Maravai Lifesciences Holdings Inc (MRVI)
$6.50
$-0.24
(-3.49%)
As on 11-Sep-2026 13:39EDT
Market cap
$2,711 Mln
Revenue (TTM)
$209 Mln
P/E Ratio
--
P/B Ratio
5.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
148,989,545
6 Years Aggregate
CFO
$1,206.89 Mln
EBITDA
$1,338.41 Mln
Net Profit
$894.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
| 99.8 | 7.0 | 27.9 | 149.8 | -15.7 | -32.7 | -- |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
| -40.4 | -16.7 | -54.2 | -65.8 | 49.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
|
6.5 | 2,711.0 | 208.8 | -77.4 | -53.9 | -9 | -- | 5.4 |
| 83.9 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 74.0 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 56.4 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.5 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 347.8 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 533.6 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 590.1 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 | |
| 338.1 | 9,822.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.4 |
Shareholding Pattern
View DetailsAbout Maravai Lifesciences Holdings Inc (MRVI)
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia... Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California. Read more
-
Co-Founder & Executive Chairman
Mr. Carl W. Hull
-
Co-Founder & Executive Chairman
Mr. Carl W. Hull
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Maravai Lifesciences Holdings Inc (MRVI)
What is the current share price of Maravai Lifesciences Holdings Inc (MRVI) Today?
The share price of Maravai Lifesciences Holdings Inc (MRVI) is $6.50 (NASDAQ) as of 11-Sep-2026 13:39 EDT. Maravai Lifesciences Holdings Inc (MRVI) has given a return of -15.67% in the last 3 years.
What is the current PB & PE ratio of Maravai Lifesciences Holdings Inc (MRVI)?
Since, TTM earnings of Maravai Lifesciences Holdings Inc (MRVI) is negative, P/E ratio is not available.
The P/B ratio of Maravai Lifesciences Holdings Inc (MRVI) is 5.35 times as on 04-Sep-2026, a 0 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.61 |
2.22 |
2024 |
-5.26 |
2.34 |
2023 |
-7.27 |
2.08 |
2022 |
8.56 |
3.46 |
2021 |
28.07 |
16.20 |
What is the 52 Week High and Low of Maravai Lifesciences Holdings Inc (MRVI)?
The 52-week high and low of Maravai Lifesciences Holdings Inc (MRVI) are Rs 9.42 and Rs 2.55 as of 12-Sep-2026.
What is the market cap of Maravai Lifesciences Holdings Inc (MRVI)?
Maravai Lifesciences Holdings Inc (MRVI) has a market capitalisation of $ 2,711 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Maravai Lifesciences Holdings Inc (MRVI)?
Before investing in Maravai Lifesciences Holdings Inc (MRVI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.